AbbVie invests USD380M in Illinois manufacturing facilities to increase API production

USA—AbbVie continues to expand its domestic manufacturing footprint with a USD 380 million investment in two new active pharmaceutical ingredient (API) facilities at its North Chicago, Illinois campus.

 The announcement marks another step in the pharmaceutical giant’s ambitious USD 100 billion commitment to U.S. research and development and capital investments.

Advanced technology powers new production sites

The two new facilities will incorporate cutting-edge manufacturing technologies enhanced by artificial intelligence.

These plants will support the production of AbbVie’s next-generation neuroscience and obesity medications.

Construction begins this spring, with both facilities expected to reach full operational capacity by 2029.

Job creation and workforce growth

AbbVie plans to hire 300 new employees for the facilities, targeting engineers, scientists, manufacturing operators, and lab technicians in the North Chicago area.

The company currently employs more than 11,500 workers in Illinois and maintains a total U.S. workforce of approximately 29,000 people.

“This milestone demonstrates further progress against our USD 100 billion commitment to U.S. R&D and capital investments over the next decade,” CEO Robert Michael stated.

“By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients.”

Building on earlier manufacturing initiatives

AbbVie launched the first phase of its U.S. API capacity expansion last September by breaking ground on a USD195 million chemical synthesis facility, also in North Chicago.

That plant will help relocate API production for select neuroscience, immunology, and oncology products from Europe and Asia back to the United States.

The company initially pledged USD 10 billion for U.S. operations over ten years last April.

AbbVie then dramatically increased this commitment to USD 100 billion in January, coinciding with a drug pricing agreement with the White House that included selling certain medicines through TrumpRx.gov, the government’s direct-to-patient drug purchasing portal.

Broader manufacturing expansion

Beyond API facilities, AbbVie continues diversifying its U.S. manufacturing presence.

The company allocated USD 70 million to expand its bioresearch center in Worcester, Massachusetts.

Additionally, AbbVie announced plans to acquire a drug device manufacturing plant in Arizona from West Pharmaceutical Services for more than USD 175 million, covering acquisition, modernization, and integration costs.

Industry-wide trend toward domestic production

AbbVie’s investment surge reflects a broader shift in the pharmaceutical industry toward domestic manufacturing.

Major drugmakers began prioritizing U.S. production facilities last year in response to the Trump administration’s tariff policies.

The company signals that its expansion plans remain far from complete.

AbbVie expects to announce additional investments throughout 2026 and currently maintains active discussions with multiple U.S. states regarding potential production projects.

These ongoing negotiations suggest the pharmaceutical manufacturer will continue strengthening its domestic manufacturing capabilities well beyond its current commitments.